---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-310422"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T16:36:35.782198+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q3 product rev $167M; Founder CEO to step down, Greenstreet to become CEO Jan 2022

## Summary
- Q3 2021 net product revenues $167M (ONPATTRO $120M, GIVLAARI $32M, OXLUMO $15M); GAAP net loss $204.5M ($1.72 loss per share).
- FY 2021 guidance reiterated: combined net product revenues $640M-$665M; GAAP R&D+SG&A $1.335B-$1.455B.
- Founding CEO John Maraganore to step down Dec 31, 2021; President/COO Yvonne Greenstreet appointed CEO effective Jan 1, 2022.
- Maraganore to consult through Mar 31, 2022 and remain on Scientific Advisory Board; Greenstreet also appointed to Board.
- Cash and investments $2.33B as of Sep 30, 2021, up from $1.87B at Dec 31, 2020 due to Blackstone payment and credit facility draw.

## SEC filing metadata
- accession: 0001193125-21-310422
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312521310422/0001193125-21-310422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312521310422/d240930d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-310422
- JSON: https://secwatch.observer/filing/0001193125-21-310422.json
- Plain text: https://secwatch.observer/filing/0001193125-21-310422.txt

## Key facts
- Executive change
  Yvonne L. Greenstreet was appointed as Director at ALNYLAM PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Director
  source text: the Board expanded the size of the Board from eleven to twelve members and elected Dr. Greenstreet to fill the newly created vacancy, in each case effective as of October 28, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312521310422/0001193125-21-310422-index.htm
- Executive change
  John M. Maraganore departed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..
  - Action: departed
  - Role: Chief Executive Officer
  source text: The Company also announced that, as part of this leadership transition, following nearly 19 years of service, John M. Maraganore, Ph.D., will depart from his position as Chief Executive Officer of the Company and as a member of the Board, effective December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312521310422/0001193125-21-310422-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.